Published in Science on February 08, 1991
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Understanding protein non-folding. Biochim Biophys Acta (2010) 4.33
Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem (2011) 3.57
A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2008) 3.46
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22
Prions. Cold Spring Harb Perspect Biol (2011) 3.17
The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J (1992) 3.04
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A (2001) 2.97
Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci (2013) 2.90
The many faces of tau. Neuron (2011) 2.89
Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem (2011) 2.86
TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol (2010) 2.81
O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 2.67
Would decreased aluminum ingestion reduce the incidence of Alzheimer's disease? CMAJ (1991) 2.58
Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A (2004) 2.48
Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci (2003) 2.35
Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 2.27
Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol (1992) 2.20
Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J (1992) 2.16
Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res (2010) 2.07
Mitotic mechanisms in Alzheimer's disease? J Cell Biol (1996) 2.00
The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci U S A (1993) 1.99
A nucleated assembly mechanism of Alzheimer paired helical filaments. Proc Natl Acad Sci U S A (1998) 1.97
Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol (1992) 1.95
An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A (1991) 1.93
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A (1993) 1.92
Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A (2003) 1.90
Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A (1997) 1.89
Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol (1996) 1.87
Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol (1991) 1.86
Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J (1994) 1.85
Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J (1995) 1.77
Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell (2002) 1.76
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
A decade and a half of protein intrinsic disorder: biology still waits for physics. Protein Sci (2013) 1.74
Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A (1994) 1.74
Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev (2007) 1.72
Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci U S A (1998) 1.71
Genetic modifiers of tauopathy in Drosophila. Genetics (2003) 1.70
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci U S A (1995) 1.67
Drosophila models of neurodegenerative diseases. Annu Rev Pathol (2009) 1.67
Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A (2003) 1.67
PICALM modulates autophagy activity and tau accumulation. Nat Commun (2014) 1.60
Neuropathology of Alzheimer's disease. Mt Sinai J Med (2010) 1.57
Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol (1992) 1.55
The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm (Vienna) (2006) 1.50
Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A (2007) 1.50
Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol (1996) 1.47
Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci U S A (1996) 1.45
New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics (2008) 1.44
Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J (1997) 1.42
Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol (2013) 1.42
Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Natl Acad Sci U S A (2007) 1.41
Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc Natl Acad Sci U S A (1991) 1.41
Berberine attenuates axonal transport impairment and axonopathy induced by Calyculin A in N2a cells. PLoS One (2014) 1.40
Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am J Pathol (1994) 1.40
RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion (2011) 1.40
Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. Mol Biol Cell (2000) 1.39
Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain (2012) 1.38
Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell (2007) 1.37
Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol (2005) 1.37
Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol (1994) 1.37
Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol (2000) 1.28
Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am J Pathol (2001) 1.28
Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease. J Proteome Res (2009) 1.27
Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol (1994) 1.27
Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau. Proc Natl Acad Sci U S A (1992) 1.26
Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol (1999) 1.24
Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.23
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.23
Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol (1995) 1.23
Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. Proc Natl Acad Sci U S A (1994) 1.22
Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos Trans R Soc Lond B Biol Sci (1999) 1.21
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med (2007) 1.21
A novel tau transcript in cultured human neuroblastoma cells expressing nuclear tau. J Cell Biol (1993) 1.20
A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. Brain (2010) 1.20
Beta protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. Am J Pathol (1992) 1.20
The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol Biol Cell (1999) 1.17
Dynamics of human keratin 18 phosphorylation: polarized distribution of phosphorylated keratins in simple epithelial tissues. J Cell Biol (1995) 1.16
The role of tau kinases in Alzheimer's disease. Curr Opin Drug Discov Devel (2010) 1.15
Markers of axonal injury in post mortem human brain. Acta Neuropathol (1994) 1.14
Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Mol Neurodegener (2007) 1.13
Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J Neurosci (2008) 1.13
Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site. Acta Neuropathol (1992) 1.12
Paired helical filament tau in Alzheimer's disease. The kinase connection. Am J Pathol (1994) 1.12
Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J Neuropathol Exp Neurol (2008) 1.11
Cell cycle-dependent phosphorylation and microtubule binding of tau protein stably transfected into Chinese hamster ovary cells. Mol Biol Cell (1995) 1.10
Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett (2011) 1.10
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (Vienna) (2009) 1.10
Interaction of aluminum with PHFtau in Alzheimer's disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method. Am J Pathol (1999) 1.10
Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS One (2011) 1.10
Characterization of a shared epitope in cortical Lewy body fibrils and Alzheimer paired helical filaments. Acta Neuropathol (1994) 1.09
Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc Natl Acad Sci U S A (1994) 1.09
Alzheimer disease and the prion disorders amyloid beta-protein and prion protein amyloidoses. Proc Natl Acad Sci U S A (1993) 1.08
Amyloidogenesis of natively unfolded proteins. Curr Alzheimer Res (2008) 1.08
Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol (2009) 1.08
Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem (2009) 1.08
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science (1994) 5.10
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature (1995) 4.18
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem (2000) 3.97
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron (1999) 3.49
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Epitopes that span the tau molecule are shared with paired helical filaments. Neuron (1988) 3.28
Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem (1995) 3.17
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology (2006) 2.65
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Synucleinopathies: clinical and pathological implications. Arch Neurol (2001) 2.36
Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest (1992) 2.30
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A (1999) 2.30
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci (2001) 2.16
Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns. J Neurosci (1987) 2.15
Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem (1999) 2.13
Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A (1998) 2.13
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron (1994) 2.13
Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology (2005) 2.10
Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology (2007) 2.09
Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A (1996) 2.08
Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen (2008) 2.00
Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro. J Virol (1985) 2.00
The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci U S A (1993) 1.99
Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol (1997) 1.98
A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res (2000) 1.97
Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol (1997) 1.95
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (2000) 1.92
Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A (1999) 1.91
Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol (1998) 1.89
Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology (2010) 1.89
Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J (1998) 1.89
Age-dependent synuclein pathology following traumatic brain injury in mice. Exp Neurol (2003) 1.89
Identification of the major multiphosphorylation site in mammalian neurofilaments. Proc Natl Acad Sci U S A (1988) 1.87
Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol (1991) 1.86
Biomarkers for early detection of Alzheimer pathology. Neurosignals (2007) 1.86
Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol (2001) 1.84
Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology (2004) 1.82
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol (2000) 1.80
Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann Neurol (2001) 1.75
Phosphate dependent and independent neurofilament epitopes in the axonal swellings of patients with motor neuron disease and controls. Lab Invest (1987) 1.73
The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry (2001) 1.70
Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem (1995) 1.70
Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology (2003) 1.66
Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiol Aging (2004) 1.64
Progressive atrophy and neuron death for one year following brain trauma in the rat. J Neurotrauma (1997) 1.64
Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol (2000) 1.63
Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology (2010) 1.63
Experimental brain injury induces regionally distinct apoptosis during the acute and delayed post-traumatic period. J Neurosci (1998) 1.62
Evidence of apoptotic cell death after experimental traumatic brain injury in the rat. Am J Pathol (1995) 1.62
Enduring cognitive, neurobehavioral and histopathological changes persist for up to one year following severe experimental brain injury in rats. Neuroscience (1998) 1.60
Mild head injury increasing the brain's vulnerability to a second concussive impact. J Neurosurg (2001) 1.59
Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol Exp Neurol (1999) 1.55
Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol (2000) 1.52
Dual targeting of cytochrome P4502B1 to endoplasmic reticulum and mitochondria involves a novel signal activation by cyclic AMP-dependent phosphorylation at ser128. EMBO J (1999) 1.52
Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J Neuropathol Exp Neurol (1985) 1.51
Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol (2000) 1.50
TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology (2010) 1.49
Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. Neurology (2008) 1.48
Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease. Acta Neuropathol (2001) 1.48
Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. Ann Neurol (1997) 1.48
Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol (1996) 1.47
A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem (1997) 1.47
PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol (2001) 1.46
Expression and analysis of presenilin 1 in a human neuronal system: localization in cell bodies and dendrites. Proc Natl Acad Sci U S A (1996) 1.46
Apolipoprotein E genotype in schizophrenia: frequency, age of onset, and neuropathologic features. Neuroreport (1997) 1.46
Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia. Ann Neurol (1996) 1.45
Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int (2001) 1.42
Expression of neurofilament subunits in neurons of the central and peripheral nervous system: an immunohistochemical study with monoclonal antibodies. J Neurosci (1986) 1.42
Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett (1999) 1.42